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Abstract
Objective: Insulin is recommended as an appropriate treatment in type 2 diabetes patients with suboptimal glycemic
control; however, its initiation is often delayed. We therefore conducted the DAWN (Diabetes Attitudes, Wishes and Needs)
JAPAN study in an attempt to identify specific patient- and physician-related factors which contribute to delay of insulin
initiation among Japanese patients with diabetes. In this report, we explored barriers for physicians which prevent timely
insulin initiation.
Methods: The DAWN JAPAN study is a multicenter, questionnaire-based survey, conducted between 2004 and 2005.
Participating physicians were categorized as follows based on their expertise: Japan Diabetes Society (JDS) certified
specialists (n=77), JDS-affiliated physicians (n=30), and non-JDS-affiliated physicians (n=27). To assess physician barriers to
insulin initiation, we have used a newly developed 27- item questionnaire.
Results: The mean age of patients (n=11,656) treated by participating physicians was 64.1 years. The mean duration of
diabetes was 121.6 months, and their mean HbA1c was 7.5%. Insulin was used in 27.4% of total patients. With regard to
physician barriers to insulin initiation, the biggest differences in concerns expressed by JDS-certified specialists and non-
JDS-affiliated physicians were observed in the following items with statistical significance: ‘‘I do not have staff (nurse,
pharmacists) who can assist with explanations’’ (1.3% vs 55.5%, respectively), ‘‘I have concerns about the use of insulin
therapy in elderly patients’’ (38.1% vs 81.5%), and ‘‘It is difficult to provide guidance and education on insulin injection to
patients’’ (16.9% vs 55.5%). The mean HbA1c at which physicians responded they would recommend insulin to their
patients was 8.7%; however, they would reduce this level to 8.2% if they themselves required insulin.
Conclusions: Our results demonstrated that physicians have concerns about insulin use, and suggested that their concerns
can lead to delay of insulin initiation.
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Introduction
Strict glycemic control in type 2 diabetes mellitus (T2D) can
prevent the onset and progression of diabetic complications [1,2].
Nonetheless, achievement of recommended glycemic targets in
patients with T2D in Japan remains less than optimal. According
to the Diabetes Mellitus Treatment Guidelines published by the
Japan Diabetes Society (JDS), an HbA1c level of $8.4% (JDS) is
considered ‘‘unacceptable’’ and represents the level at which
treatment needs re-evaluating. Insulin treatment would be strongly
recommended when HbA1c #7.0% cannot be achieved with oral
antidiabetic agents (OADs), but initiation of insulin is often
delayed mainly due to patients’ hesitation to start insulin treatment
[3–11] even in insufficient glycemic control [12].
The DAWN study, a cross-sectional international survey
initiated in 2001 by Novo Nordisk in collaboration with the
International Diabetes Federation, was conducted to identify a
broad set of attitudes, wishes, and needs among both people with
diabetes and care providers (physicians and nurses), consisting of
more than 5,000 patients with diabetes and nearly 4,000 care
providers in a total of 13 countries participated in [13]. The survey
demonstrated that the most significant factor preventing the
initiation of insulin therapy was patient resistance [13–15]. In
addition, physician barriers to insulin initiation were demonstrated
with the result that approximately 40% of physicians did not
prefer to initiate insulin unless it became ‘‘absolutely necessary’’
[16] although most physicians recognized that insulin was an
efficacious approach to the management of T2D [17].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e36361On the basis of these key findings from the international DAWN
study, we planned a series of surveys as the DAWN JAPAN study
attempting to identify specific factors which contribute to delay of
insulin initiation among both Japanese physicians and patients. As
a better understanding of the barriers to insulin initiation both in
physicians and patients is developed, more appropriate strategies
can be implemented to encourage timely insulin initiation. This
paper reports the survey results relevant to understanding
physician barriers to insulin initiation in Japan.
Methods
Design and the Survey Process of the DAWN JAPAN
Study
The DAWN JAPAN study is a multicenter, questionnaire-
based survey, conducted between 2004 and 2005. Both
physicians and patients participated in this study. The partici-
pating physicians were categorized based on the following: JDS-
certified specialists, JDS-affiliated physicians, and non-JDS-
affiliated physicians. The participating physicians of the each
category were selected from throughout Japan roughly at a ratio
of 2:1:1. As a patient sample, patients with T2D either treated
with insulin or not, who were under care of participating
physicians, were included in the survey.
The survey process of the DAWN JAPAN study is shown in
Figure 1. Participating physicians first completed Questionnaire A,
assessing their attitudes towards insulin as a treatment for T2D.
The same physicians then completed Questionnaire B to obtain
treatment status of the patients with T2D they treated during a 1-
month period, up to a maximum of 100 patients. Of the patients
whose treatment status was collected in Questionnaire B, those
who were recommended to start insulin in the participating sites
were asked to complete Questionnaire C, which examined their
perceptions of insulin treatment. Of these patients, those who
subsequently chose to start insulin treatment answered Question-
naire D a month after the start of insulin treatment to examine
whether their attitudes toward to insulin would change after
insulin had been initiated. Also, those who chose not to start
insulin filled out Questionnaire E, 4 months after the end of
Questionnaire B completion period to examine a change of their
attitudes toward insulin treatment. The attending physicians filled
out Question D1 or E1 to assess treatment status of their patients
who completed either Questionnaire D or E a month after the
completion of each questionnaire.
Due to the non-interventional nature of this study, the study
protocol was approved centrally by the ethics committee of the
DAWN JAPAN study group. The ethics committee of the DAWN
JAPAN study group was responsible for the ethical and scientific
quality of the study. The study was conducted in accordance with
the Declaration of Helsinki [18] and with the Ethical Guidelines
related to Epidemiological Research [19]. A written informed
consent was obtained from all the participating patients in this
survey.
Assessment of Physician Barriers to Insulin Initiation
To assess physician barriers to insulin initiation, we developed
27-item questionnaire named the Physicians Attitude to Insulin
Therapy questionnaire (PAINT), and included it in Question-
naire A. A five-point Likert scale (1. completely agree; 2. mostly
agree; 3. neither agree nor disagree; 4. mostly disagree; 5.
completely disagree) was employed in the PAINT. Content
validity of the PAINT was assured based on review by DAWN
JAPAN advisory panel and a pilot-test on a relevant sample of
physicians. The psychometric properties of the PAINT were
assessed by using the collected questionnaires in this survey.
Internal consistency was excellent with cronbach a coefficient of
0.94. Exploratory cluster analysis demonstrated that the PAINT
consisted of 5 clusters: ‘‘Issues with the doctor’s experience’’,
‘‘Burden related to explanations’’, ‘‘Consideration of burden on
patients’’, ‘‘Concerns regarding insulin therapy’’, and ‘‘Concerns
regarding hypoglycemia’’. The second eigenvalues in each
cluster were 0.81, 0.65, 0.71, 0.77, and 0.89, respectively.
The proportion of total variation explained was 0.61.
In addition to the PAINT, the participating physicians were
asked to answer their treatment strategies of T2D and HbA1c level
at which insulin initiation was recommended. Treatment status of
their patients including currently receiving treatment, past
diabetes history, and current HbA1c were collected using
Questionnaire B. The value for HbA1c (%) is estimated as a
National Glycohemoglobin Standardization Program (NGSP)
equivalent value (%) calculated by the formula: HbA1c (%) =
HbA1c (JDS value) +0.4, considering the relational expression of
HbA1c (JDS value) (%) measured by the previous Japanese
standard substance and measurement methods and HbA1c [20].
Statistical Analysis
The physicians who completed both the Questionnaire A and B
were included into the analysis set for PAINT assessment.
Descriptive analyses were performed on background data of
physicians and their patients by the physician subgroups: JDS-
certified specialists, JDS-affiliated physicians, and Non-JDS-
affiliated physicians. In the analyses of the PAINT, a response
distribution of each item was calculated, and the equality of
distribution among the physician subgroups was analyzed using
Kruskal–Wallis one-way analysis of variance by ranks test. A
stepwise multiple linear regression analysis was conducted to
explore which PAINT items are predictive of the rate of insulin
use. The rate of insulin use was calculated by dividing the number
of patients treated with insulin therapy by the number of patients
with T2D treated in a month.
Statistical Package SAS Release 9.1 was used for the analyses.
All statistical tests were two-tailed, and the level of statistical
significance was set at 5%.
Results
In total, 134 physicians completed both Questionnaire A and
Questionnaire B (Table 1). JDS-certified specialists treated more
patients per month than the other physician groups. Only 3.7% of
physicians had no experience providing insulin therapy. Staff who
is capable of providing guidance on diabetes treatment (nurses,
pharmacists, or other staff) is present in 76.1% of the participating
institutions in total, but 70.4% of non-JDS-affiliated physicians
had no access to this support. The mean HbA1c at which
physicians responded they would recommend insulin to their
patients was 8.760.7% although if they themselves required
insulin, the physicians responded they would reduce this level to
8.260.7% (Figure 2).
The background information of 11,656 patients with T2D
treated by the participating physicians was obtained from
Questionnaire B (Table 1). Overall, mean HbA1c (6SD) was
7.561.3%. Regarding treatments being received, 17.8% of
patients were receiving diet and exercise therapy only, 54.8%
were using oral antidiabetic drugs (OADs) only, and 27.4% of
patients were using insulin (alone or in combination with OADs).
Of the patients treated by JDS-certified specialists, 33.0% were
using insulin (alone or in combination with OADs), compared
with 23.1% and 10.4% of patients treated by JDS-affiliated and
Physician Barriers to Insulin Initiation
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0.4 points higher in patients of JDS-certified specialists than in
patients in other physician groups. The duration of diabetes was
longer in patients of JDS-certified specialists than in other
groups.
Of the patients surveyed in Questionnaire B, insulin treatment
was recommended to 236 patients (2.0%) on the day they visited
the hospital/clinic. The mean HbA1c (6SD) in patients recom-
mended insulin was 9.661.5% (Figure 2). Of patients with an
HbA1c $8.4% (n=2,346; 20.1%), insulin was recommended to
just 192 patients (8.2%).
Figure 1. The survey process of DAWN JAPAN study.
doi:10.1371/journal.pone.0036361.g001
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Overall Physician subgroup P value
JDS-certified
specialists
JDS-affiliated
physicians
Non-JDS-affiliated
physicians
Physician sample (n, % or
mean 6SD)
134 77 57.5% 30 22.4% 27 20.1%
Age (years) 134 48.368.4 77 49.667.6 30 44.5611.0 27 48.765.6 ,0.0001{
Sex (male) 115 85.8% 65 84.4% 24 80.0% 26 96.3% 0.183821
Type of work 115 85.8% 65 84.4% 24 80.0% 26 96.3% 0.183821
Private practice 79 59.0% 37 48.1% 18 60.0% 24 88.9%
Working at a hospital 55 41.0% 40 51.9% 12 40.0% 3 11.1%
Number of patients with
type 2 diabetes per month
134 325.46282.7 77 437.66269.6 30 185.86162.5 27 75.4647.0 ,0.0001{
Number of insulin-treated
patients with type 2
diabetes per
month
134 83.8685.1 77 126.2684.5 30 42.8652.0 27 8.765.9 ,0.0001{
Experience providing insulin
therapy:
0.129281
No 5 3.7% 1 1.3% 2 6.7% 2 7.4%
Yes 129 96.3% 76 98.7% 28 93.3% 25 92.6%
Staff capable of providing
guidance on diabetes
treatment:
,0.00011
Absent 32 23.9% 4 5.2% 9 30.0% 19 70.4%
Present 102 76.1% 73 94.8% 21 70.0% 8 29.6%
Implementation of patient
education (classrooms)
regarding diabetes:
,0.00011
Not implemented 40 30% 6 7.9% 12 40.0% 22 81.5%
Irregularly implemented 24 18% 15 19.7% 6 20.0% 3 11.1%
Regularly implemented 69 51.9% 55 72.4% 12 40.0% 2 7.4%
The HbA1c value at which
I would consider insulin
therapy for type 2
diabetes patients
134 8.760.7 77 8.760.7 30 8.660.5 27 9.160.8 ,0.0001{
The HbA1c value at which
I would initiate insulin
therapy if I were a type 2
diabetes patient
134 8.260.7 77 8.060.6 30 8.160.5 27 8.661.0 ,0.0001{
Patients treated by
participating physicians
(n, % or mean 6SD)
11,656 7,403 64.6% 2,224 19.4% 1,829 16.0%
Age (years) 11,621 64.1611.8 7,384 63.2611.8 2,218 65.6611.6 1,821 65.9611.1 ,0.0001{
Sex (male) 6,344 54.9% 4,112 56.1% 1,166 52.8% 947 52.2% 0.000981
HbA1c (%) 11,583 7.561.3 7,359 7.661.3 2,207 7.361.3 1,818 7.261.3 ,0.0001{
BMI 11,391 24.263.8 7,193 24.163.8 2,198 24.463.9 1,802 24.463.8 ,0.0001{
Duration of diabetes (months) 11,326 121.6699.7 7,134 134.06102.2 2,194 109.9693.6 1,798 88.4688.3 ,0.0001{
Current Treatment: ,0.00011
Diet and exercise only 2,071 17.8% 1,105 15.0% 431 19.4% 480 26.3%
OADs only 6,378 54.8% 3,843 52.0% 1,274 57.4% 1,156 63.3%
Insulin only 1,952 16.8% 1,545 20.9% 267 12.0% 112 6.1%
OAD + insulin 1,235 10.6% 898 12.1% 247 11.1% 79 4.3%
SD: standard deviation; P values were calculated by using chi-square test (1) or ANOVA ({).
doi:10.1371/journal.pone.0036361.t001
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The result of the PAINT is shown in Table 2. The percentage of
expressing concerns relate to insulin (cumulative response of
‘‘completely agree’’ and ‘‘mostly agree’’) were significantly
different in the items among the physician groups except following
items: ‘‘The patient would have to pay more for treatment’’
(P=0.1576), ‘‘There is a higher risk of hypoglycemia with insulin
therapy compared to other therapies’’ (P=0.2168), and ‘‘Com-
pliance with insulin therapy tends to be low’’ (P=0.1799). The
three most reported concerns were the same regardless of the
expertise of the physician: ‘‘The patients would have to pay more
for treatment’’ (76.6%, 53.3%, and 62.9%, for JDS-certified
physicians, JDS-affiliated physicians, and non-JDS-affiliated phy-
sicians, respectively), ‘‘Patients would resist insulin therapy’’
(48.1%, 56.7%, 81.4%, respectively), and ‘‘I have concerns about
the use of insulin therapy in elderly patients’’ (38.1%, 43.3%,
81.5%, respectively).
JDS-certified specialists exhibited less concern over insulin use
than other physician groups. More than 30% differences in
concerns between JDS-certified specialists and non-JDS-affiliated
physicians were observed in the following items: ‘‘I’m not familiar
with insulin therapy’’ (2.6% vs 37.0%, respectively), ‘‘It is difficult
to select the type of insulin and adjust the dose’’ (3.9% vs 37.0%),
‘‘It is time-consuming to explain injection methods and the use of
injection devices’’ (15.6% vs 51.8%), ‘‘I do not have staff (nurse,
pharmacists) who can assist with explanations’’ (1.3% vs 55.5%),
‘‘It is difficult to provide guidance and education on insulin
injection to patients’’ (16.9% vs 55.5%), ‘‘Patients would resist
insulin therapy’’ (48.1% vs 81.4%), ‘‘I have concerns about the use
of insulin therapy in elderly patients’’ (38.1% vs 81.5%).
A stepwise multiple linear regression analysis indicated four
PAINT items as independent determinants which affect the rate of
insulin use. A positive correlation was demonstrated in the
following variables: ‘‘My clinic/hospital is not equipped to provide
insulin therapy’’ (b=0.334), ‘‘If necessary, I can refer the patients
to a specialist’’ (b=0.230), and ‘‘My clinic/hospital is unable to
provide treatment for hypoglycemia’’ (b=0.191). However, a
negative correlation was observed in ‘‘I do not have time to
persuade patients to undergo insulin therapy or provide guidance
on it’’ (b=20.257), (Table 3).
Discussion
The present analyses provide important insights into current
treatment preferences and physician barriers to insulin initiation in
Japan. Our survey results of 134 Japanese physicians show that, in
the management of diabetes, non-diabetes specialists have more
concerns about insulin initiation than specialists, and that most of
the concerns among non-specialists are related to practical
burdens.
The data on the male/female ratio, age, BMI and HbA1c values
of the 11,656 patients with T2D surveyed in this study are similar
to previously reported information on patients with T2D in Japan
[21,22]. Our data show that patients with T2D in Japan
apparently have unsatisfactory control of HbA1c with a mean of
7.5%. Approximately 20% of patients were still in suboptimal
control (HbA1c .8.4%).
Physician barriers to insulin initiation were suggested by an
HbA1c level at which physicians would initiate or initiated
insulin. More than 90% of patients with HbA1c level of .8.4%
were not recommended insulin. The physicians stated that they
would use insulin at an HbA1c level of 8.2% for themselves if
they themselves required insulin. This value is close to an HbA1c
level of 8.4% which was categorized as ‘‘unacceptable’’ in
treatment guidelines including JDS and ADA, and therefore
considered insufficiently high enough for insulin initiation. In
Figure 2. Gap between considered and actual recommended level of HbA1c. HbA1c level at which insulin therapy would be recommended
was compared to actual level at which insulin therapy was recommended (mean 6 SD).
doi:10.1371/journal.pone.0036361.g002
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achievement of adequate glycemic control in the diabetes
management, are not going to start insulin under the exposure
of an insufficient HbA1c level which can increase a risk of
subsequent diabetic complications, and it is partially suggested
that physicians underestimate the importance of achieving a
targeted HbA1c level recommended by the guidelines. Compared
with this value, an HbA1c level at which physicians responded
they would recommend insulin to their patients have increased
by 0.5% to 8.7%. An assumption of patient resistance for insulin
initiation may be one possible explanation delaying an introduc-
tion of insulin therapy to the patients. Under this assumption,
physicians may hesitate to introduce insulin therapy timely. In
addition, the gap was observed between this HbA1c value and
actual value at which insulin therapy was recommended to
patients. Patients were actually recommended insulin therapy at
an HbA1c level of 9.6%. This discordance is referred to as
clinical inertia. Clinical inertia is defined as the recognition of a
problem with a patient’s management but a failure to act [23].
Factors contributing to clinical inertia can include an assumption
of patient resistance, actual resistance by the patients, failure to
set clear target level, or insufficient communication with patients.
The result of PAINT showed physicians’ concerns over insulin
use as potential factors contributing clinical inertia observed in this
study. Non-JDS-affiliated physicians were particularly concerned
about practical burdens related to giving explanation to the patient
such as time required to explain and train patients to inject,
difficulties explaining blood glucose monitoring and hypoglycemia
management, or few trained support staff to guide patients.
Preparing an explanatory material to facilitate explanations to
patients may help reduce these burdens. In contrast, JDS-certified
specialists reported insulin-related concerns less frequently overall.
Problems related to complexity of insulin therapy such as
determining insulin type and dose were not often observed, which
may be due to sufficient experience of using insulin and
comprehensive knowledge of diabetes and insulin in this group.
The concerns most frequently expressed by the specialists were
related to cost of therapy and use in the elderly. While there is less
scope for overcoming barriers in JDS-certified specialists as
practical barriers were rarely cited as a concern, specialists may
benefit from an explanatory material to encourage patient
acceptability of insulin since nearly 50% of specialists answered
that patient would resist insulin therapy. An explanatory material
specifically for elderly patients might be also useful. Although few
concerns for insulin use were expressed by JDS-certified specialists,
it should be noted that physicians may not introduce insulin
therapy only with one single reason. Based on stepwise multiple
linear regression analysis, four PAINT items were indicated as the
predictive factors associating the lower rate of insulin use. Of these,
the item ‘‘I do not have time to persuade patients to undergo
insulin therapy or provide guidance on it’’ negatively correlated
with the lower rate of insulin use. The one possible explanation is
that physicians or other staff actually managed to give guidance or
explanation to the patients if necessary even though physicians did
not enough time. Or possibly, physicians who administrate insulin
more frequently might perceive that they do not have enough time
to give appropriate guidance.
While literature [16,17,24–27] frequently indicates physician
barriers to insulin initiation, few studies have examined these
barriers in detail. In the international DAWN study, it was
reported that approximately 40% of physicians would delay
insulin until absolutely necessary [14]. In a study of 157 family
physicians in Israel, Nakar et al examined the reasons for non-
initiation of insulin in patients meeting initiation criteria. More
than 90% of physicians reported that patients would not comply
with treatment, nearly 80% cited concerns over hypoglycemia,
approximately 50% were worried that patients would not cope
with the pain (of injecting or blood glucose measurements), and
47% were concerned about patients’ age [28]. Just 27% cited no
experience with treatment as a barrier to initiation [28]. It is
difficult to compare studies directly due to differences in design,
question structure and cultural background; however, the physi-
cians in the DAWN JAPAN study appeared less concerned about
hypoglycemia, although both studies did identify that using insulin
in elderly people was frequently a concern. In our study fewer than
5% of physicians were concerned about compliance with
treatment.
There is a limitation that needs to be acknowledged and
addressed regarding the present study. The limitation has to do
with the extent to which physician barrier to insulin therapy
actually delay the insulin initiation. The findings of this study did
not show how strongly each factor would affect the initiation delay.
Future assessments are necessary to address this issue.
In conclusion, our results show that physicians do have concerns
about insulin use that may delay insulin initiation. As expected,
non-specialists reported more concerns than specialists, even
though both specialists and non-specialists appeared to delay
insulin use frequently. Understanding physician barriers to insulin
use is important to ensure that appropriate strategies can be
employed to overcome these barriers.
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